STREAM-2: Half-Dose Tenecteplase vs Primary PCI in Older Patients with STEMI?
REBEL EM
SEPTEMBER 28, 2023
Paper: Van de Werf, F et al. The STREAM-1 trial found that for [2] patients with STEMI presenting within 3 hours of symptom onset and unable to attain PCI within 1 hour of first medical contact, a pharmaco-invasive strategy resulted in similar rates of death, shock, heart failure, or reinfarction compared to primary PCI.
Let's personalize your content